Clinical and Laboratory Analysis of Familial Cancer

NCT ID: NCT02565004

Last Updated: 2022-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

19 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-28

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

DNA makes up the instruction book for people s cells. Cancer is a disease caused by DNA changes that build up and affect cell function. Researchers want to learn more about what may cause cancer by testing the DNA of people with the disease and their family members.

Objective:

To find DNA changes that may be inherited and may cause or influence whether a person gets cancer. To study families with clusters of cancer to find out if there is a DNA mutation specific to certain cancers.

Eligibility:

People 18 years of age and older who:

Participated in the familial genetic part of NIH study 09-C-0079, a previous study or had family members enrolled in this study

Design:

Participants may have been screened in the previous study. They will give permission for researchers to use their data and their tissue or blood samples collected in the study.

Participants may give blood samples.

At each stage of testing, participants will meet with a genetics health care provider. The provider will explain the tests and answer questions.

If researchers find a DNA change that might increase the risk for cancer or other health issues, they will confirm this result in a testing lab. This will require a blood sample.

Participants personal DNA data and health information will be put in a database for research purposes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

* This study is to continue the analysis begun on 09C0079 which was focused on identification of the genetic mutation associated with a new gastric polyposis syndrome, Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS).
* GAPPS is an autosomal dominant gastric polyposis syndrome that confers a substantial risk for gastric adenocarcinoma and has been found to be associated with germline point variants in APC promoter 1B.
* At this time, any non-gastric phenotype associated with GAPPS is unknown and is being explored using a phenotyping survey interview.

Objective

\- To specifically investigate families with clusters of cancer to determine if there is a potential familial genetic mutation specific to a particular cancer and if present, to compare these genetic abnormalities with individuals from the same family without cancer.

Eligibility:

* Participants must meet one of the following:

* Have been previously enrolled on the familial genetic analysis arm of NIH study 09-C-0079; OR
* Be family members of patients previously enrolled on the familial genetic analysis arm of 09-C-0079; OR
* Have a documented pathogenic germline APC promotor 1B variant from a CLIA approved laboratory.
* Participants must be 10 years of age or older

Design:

* This protocol was originally opened to continue same use of research that was approved under protocol 09-C-0079, to analyze the data for publication, and to provide participants with any results of clinical and analytic validity and clinical utility.
* In a subsequent amendment carriers of a germline APC promoter 1B variant will participate in a phenotyping assessment survey interview to assess the phenotype of Gastric Adenocarcinoma and Proximal Polypopsis of the Stomach (GAPPS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

FAMILY_BASED

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients who were enrolled on protocol 09-C-0079, or family members of patients who were enrolled on protocol 09-C-0079

No interventions assigned to this group

2

Individuals found to harbor a germline APC promoter 1B variant not previously enrolled in Cohort l.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must meet one of the following:

* Have been previously enrolled on the familial genetic analysis arm of NIH study 09-C-0079; OR
* Be family members of patients previously enrolled on the familial genetic analysis arm of 09-C-0079; OR
* Have a documented pathogenic germline APC promotor 1B variant from a CLIA approved laboratory.
* Participants must be 10 years of age or older

Exclusion Criteria

Inability to provide informed consent.
Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Cancer Institute (NCI)

NIH

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kathleen Calzone, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

National Cancer Institute (NCI)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-C-0204

Identifier Type: -

Identifier Source: secondary_id

150204

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Omics of Cancer: OncoGenomics
NCT05431439 WITHDRAWN